S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
The A.I. story nobody is telling you (Read ASAP) (Ad)
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Wall Street rises in premarket as bond markets stabilize and earnings roll in
The only accurate crypto trading system I know … (Ad)
Closing prices for crude oil, gold and other commodities
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
The A.I. story nobody is telling you (Read ASAP) (Ad)
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Wall Street rises in premarket as bond markets stabilize and earnings roll in
The only accurate crypto trading system I know … (Ad)
Closing prices for crude oil, gold and other commodities
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
The A.I. story nobody is telling you (Read ASAP) (Ad)
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Wall Street rises in premarket as bond markets stabilize and earnings roll in
The only accurate crypto trading system I know … (Ad)
Closing prices for crude oil, gold and other commodities
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
The A.I. story nobody is telling you (Read ASAP) (Ad)
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Wall Street rises in premarket as bond markets stabilize and earnings roll in
The only accurate crypto trading system I know … (Ad)
Closing prices for crude oil, gold and other commodities
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
Free Trial

Compare Stocks

→ [Urgent!] Generational Wealth Gameplan (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Compare

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
C$1.44
-2.0%		C$1.44
C$1.20
▼
C$4.49
C$108.61M1.4980,832 shs31,075 shs
Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
-2.04%-8.28%+1.41%-8.86%-4.64%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
0.5705 of 5 stars		3.50.00.00.01.10.00.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
3.00
BuyC$6.00316.67% Upside

Current Analyst Ratings

Latest TILS, ONC, and HZD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/4/2024
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Set Price TargetOutperformC$3.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
N/AN/AC$0.34 per share4.22C$0.37 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
-C$27.75M-C$0.41N/A∞N/AN/A-102.66%-55.47%5/3/2024 (Estimated)

Latest TILS, ONC, and HZD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/7/2024Q4 2023
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
-C$0.15-C$0.05+C$0.10-C$0.05N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
1.54
9.01
8.86

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
6.98%

Insider Ownership

CompanyInsider Ownership
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
6.24%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
2975.42 millionN/ANot Optionable

TILS, ONC, and HZD Headlines

SourceHeadline
Outrun Therapeutics announces launch with $10m seed fundingOutrun Therapeutics announces launch with $10m seed funding
pharmaceutical-technology.com - April 18 at 7:38 AM
Biotech expansion for Japanese firm in Holly Springs driven by talent pool, universitiesBiotech expansion for Japanese firm in Holly Springs driven by talent pool, universities
carolinapublicpress.org - April 17 at 10:38 AM
Stocks in play: Oncolytics Biotech® Inc.Stocks in play: Oncolytics Biotech® Inc.
ca.finance.yahoo.com - April 11 at 3:56 PM
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDAOncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
finance.yahoo.com - April 11 at 8:38 AM
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
markets.businessinsider.com - April 10 at 6:01 PM
Oncolytics Biotech is undervalued, Raymond James saysOncolytics Biotech is undervalued, Raymond James says
cantechletter.com - April 5 at 3:37 PM
Oncolytics Biotech (TSE:ONC) Trading Up 10.7%Oncolytics Biotech (TSE:ONC) Trading Up 10.7%
marketbeat.com - April 4 at 10:46 AM
Closing Bell: Oncolytics Bio down on Friday (ONC)Closing Bell: Oncolytics Bio down on Friday (ONC)
theglobeandmail.com - March 16 at 10:14 AM
Futures Retreat SharplyFutures Retreat Sharply
msn.com - March 11 at 4:05 PM
Oncolytics Biotech Inc.: Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCANOncolytics Biotech Inc.: Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
finanznachrichten.de - March 6 at 4:39 PM
Econ Corp Services DBA Investorideas.com: Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth WinningEcon Corp Services DBA Investorideas.com: Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
finanznachrichten.de - March 6 at 4:39 PM
A Preview Of Oncolytics Biotechs EarningsA Preview Of Oncolytics Biotech's Earnings
benzinga.com - March 6 at 4:39 PM
Oncolytics Biotech Inc ONCOncolytics Biotech Inc ONC
morningstar.com - March 2 at 6:22 PM
Reiterating Buy Rating: Expanding Potential of Pelareorep in Oncolytics Biotech’s PipelineReiterating Buy Rating: Expanding Potential of Pelareorep in Oncolytics Biotech’s Pipeline
markets.businessinsider.com - February 15 at 9:24 AM
Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation TreatmentsCancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments
finance.yahoo.com - February 15 at 9:24 AM
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New TherapiesAnal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
theglobeandmail.com - February 14 at 2:36 PM
USA News Group: Pancreatic Cancer Treatments Poised for Major Advances in 2024USA News Group: Pancreatic Cancer Treatments Poised for Major Advances in 2024
finanznachrichten.de - February 7 at 11:03 AM
KaliVir Announces Opening of GMP Cleanroom Facility, Increasing Manufacturing Capacity for Oncolytic VirusesKaliVir Announces Opening of GMP Cleanroom Facility, Increasing Manufacturing Capacity for Oncolytic Viruses
finance.yahoo.com - January 31 at 8:47 PM
Oncolytics Biotech Stock (NASDAQ:ONCY), Analyst Ratings, Price Targets, PredictionsOncolytics Biotech Stock (NASDAQ:ONCY), Analyst Ratings, Price Targets, Predictions
benzinga.com - January 6 at 3:30 PM
JonesTrading Keeps Their Hold Rating on TRACON Pharmaceuticals (TCON)JonesTrading Keeps Their Hold Rating on TRACON Pharmaceuticals (TCON)
markets.businessinsider.com - December 14 at 8:26 AM
Oncolytics Biotech Inc.: Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCSOncolytics Biotech Inc.: Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS
finanznachrichten.de - December 7 at 8:30 AM
Oncolytics Provides Update on Pancreatic Cancer Program for PelareorepOncolytics Provides Update on Pancreatic Cancer Program for Pelareorep
finance.yahoo.com - November 9 at 7:48 AM
Oncolytics Biotechs Earnings OutlookOncolytics Biotech's Earnings Outlook
benzinga.com - November 3 at 6:37 PM
Oncolytics Biotech Inc.: Oncolytics Biotech Reports Third Quarter 2023 Financial Results and Operational HighlightsOncolytics Biotech Inc.: Oncolytics Biotech Reports Third Quarter 2023 Financial Results and Operational Highlights
finanznachrichten.de - November 3 at 1:36 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Oncolytics Biotech logo

Oncolytics Biotech

TSE:ONC
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.